{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:35:37Z","timestamp":1792089337490,"version":"4.4.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.143236","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T18:58:15Z","timestamp":1744743495000},"page":"143236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"P1","title":["Hyaluronate-incorporated edaravone nanostructured lipid carriers for nose-to-brain targeting- biphasic DoE optimization, pharmacokinetic, and brain distribution studies"],"prefix":"10.1016","volume":"310","author":[{"given":"Dhrumi","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-1741","authenticated-orcid":false,"given":"Sarika","family":"Wairkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.143236_bb0005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"A review of the ccommon neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/610813","article-title":"Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF","volume":"2015","author":"Fischer","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0015","first-page":"6","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"63","author":"Watanabe","year":"2018","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1527-3458.2006.00009.x","article-title":"Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury","volume":"12","author":"Yoshida","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/antiox11020195","article-title":"Effects of the edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection","volume":"11","author":"Cha","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0030","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/ijms25052945","article-title":"Update on antioxidant therapy with edaravone: expanding applications in neurodegenerative diseases","volume":"25","author":"Yamashita","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0035","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1039\/C8CS00805A","article-title":"Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics","volume":"48","author":"Tang","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0040","author":"USFDA"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0045","author":"USFDA"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0050","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jps.23807","article-title":"Hydroxypropyl-sulfobutyl-\u03b2-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes","volume":"103","author":"Rong","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2023.105302","article-title":"In silico and in vitro investigation of bile salts as coformers for edaravone coamorphous dispersion- part I","volume":"253","author":"Patel","year":"2023","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejps.2018.04.002","article-title":"Gastric retention pellets of edaravone with enhanced oral bioavailability: absorption mechanism, development, and in vitro\/in vivo evaluation","volume":"119","author":"Li","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0065","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2147\/DDDT.S161940","article-title":"Self-nanomicellizing solid dispersion of edaravone: part I \u2013 oral bioavailability improvement","volume":"12","author":"Parikh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijpharm.2016.10.052","article-title":"Development of a novel oral delivery system of edaravone for enhancing bioavailability","volume":"515","author":"Parikh","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/pharmaceutics16040481","article-title":"Nasal delivery to the brain: harnessing nanoparticles for effective drug transport","volume":"16","author":"Gandhi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/1061186X.2017.1350858","article-title":"Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson\u2019s disease","volume":"26","author":"Sridhar","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0085","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3109\/10717544.2015.1013587","article-title":"Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation","volume":"23","author":"Aboud","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0090","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer\u2019s disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0095","article-title":"Research progress in brain-targeted nasal drug delivery","volume":"15","author":"Huang","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43094-022-00414-8","article-title":"Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours","volume":"8","author":"Garg","year":"2022","journal-title":"Futur J Pharm Sci"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pharmaceutics12030288","article-title":"Nanostructured lipid carriers for delivery of chemotherapeutics: a review","volume":"12","author":"Haider","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119166","article-title":"Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: preparation, characterization, and in vivo evaluation","volume":"579","author":"Alshweiat","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/pharmaceutics12010040","article-title":"Hyaluronate nanoparticles as a delivery system to carry neuroglobin to the brain after stroke","volume":"12","author":"Blanco","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0130","doi-asserted-by":"crossref","first-page":"34158","DOI":"10.18632\/oncotarget.8926","article-title":"Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells","volume":"7","author":"Hayward","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11427-017-9217-2","article-title":"Application of the sodium hyaluronate-CNTF scaffolds in repairing adult rat spinal cord injury and facilitating neural network formation","volume":"61","author":"Xie","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119990","article-title":"Berberine loaded nanostructured lipid carrier for Alzheimer\u2019s disease: design, statistical optimization and enhanced in vivo performance","volume":"285","author":"Raju","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0145","unstructured":"JP XVII: The Ministry of Health Labour and Welfare, The Japanese pharmacopoeia seventeenth edition, (2016) 851\u2013853."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0150","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/molecules25061449","article-title":"Ellagic acid containing nanostructured lipid carriers for topical application: a preliminary study","volume":"25","author":"Singh Hallan","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.12928\/pharmaciana.v9i2.13070","article-title":"Entrapment efficiency and drug loading of curcumin nanostructured lipid carrier (NLC) formula","volume":"9","author":"Rabima","year":"2019","journal-title":"Pharmaciana"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.molliq.2018.01.141","article-title":"Silymarin loaded nanostructured lipid carrier: from design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement","volume":"255","author":"Iqbal","year":"2018","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejpb.2022.02.010","article-title":"Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery","volume":"172","author":"Varela-Fern\u00e1ndez","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189478","article-title":"A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases","volume":"12","author":"Wang","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","article-title":"Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity","volume":"109","author":"Raj","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0180","article-title":"Brain-targeted nasal chrysin microemulsion for reducing oxidative stress in Parkinson\u2019s disease: Pharmacodynamic, biochemical evaluation and brain distribution studies","volume":"97","author":"Adangale","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.colsurfa.2012.10.031","article-title":"Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations","volume":"416","author":"Kumbhar","year":"2013","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0190","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceutical for human use (ICH) guideline for stability testing of new drug substances and products Q1A(R2), 2003."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0195","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.pharma.2024.06.005","article-title":"Effect of food on oral pharmacokinetics of edaravone coamorphous dispersion containing bile salts as coformers \u2013 part II","author":"Patel","year":"2024","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0200","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/14737175.2015.1036743","article-title":"Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization","volume":"15","author":"Mustafa","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0205","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/10717544.2014.907372","article-title":"Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route","volume":"23","author":"Mittal","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0210","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11094-019-02017-9","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid based drug delivery systems","volume":"53","author":"Shirodkar","year":"2019","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.fhfh.2021.100024","article-title":"Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active","volume":"1","author":"Sakellari","year":"2021","journal-title":"Food Hydrocolloids for Health"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934156","article-title":"Nanostructured lipid carrier-based delivery of pioglitazone for treatment of type 2 diabetes","volume":"13","author":"Ilyas","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0225","first-page":"3346","article-title":"Neuroprotective role of coconut oil for the prevention and treatment of Parkinson\u2019s disease: potential mechanisms of action","author":"P","year":"2022","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.113734","article-title":"Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol","volume":"316","author":"Houacine","year":"2020","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11051-020-04848-0","article-title":"Optimization of nanostructured lipid carriers: understanding the types, designs, and parameters in the process of formulations","volume":"22","author":"Subramaniam","year":"2020","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0240","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceutical for human use (ICH) guideline for pharmaceutical development Q8(R2), 2009."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0245","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceutical for human use (ICH) guideline for quality risk management Q9(R1), 2021."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0250","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceutical for human use (ICH) guideline for pharmaceutical quality system Q10, 2008."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0255","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2147\/IJN.S402447","article-title":"Nose to brain delivery of astaxanthin\u2013loaded nanostructured lipid carriers in rat model of Alzheimer\u2019s disease: preparation, in vitro and in vivo evaluation","volume":"18","author":"Shehata","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2023.100031","article-title":"The effect of particle size on drug bioavailability in various parts of the body","volume":"2","author":"Mok","year":"2024","journal-title":"Pharm Sci Adv"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0265","first-page":"1134","article-title":"Physicochemical characteristics, entrapment efficiency, and stability of nanostructured lipid carriers loaded coenzyme Q10 with different lipid ratios","volume":"27","author":"Suyuti","year":"2023","journal-title":"J Res Pharm"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0270","first-page":"773","article-title":"Influence of process parameters on properties of nanostructured lipid carriers (NLC) formulation","volume":"60","author":"Laso\u0144","year":"2013","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0275","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/1061186X.2012.716845","article-title":"Nanostructured lipid carriers system: recent advances in drug delivery","volume":"20","author":"Iqbal","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0280","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1039\/C3AY90020G","article-title":"Experimental design and optimisation (4): Plackett-Burman designs","volume":"5","author":"Committee","year":"2013","journal-title":"Anal. Methods"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10601330701220520","article-title":"Design of experiments: concept and applications of plackett burman design","volume":"24","author":"Vanaja","year":"2007","journal-title":"Clin. Res. Regul. Aff."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0290","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fpsyg.2012.00322","article-title":"Statistical assumptions of substantive analyses across the general linear model: a mini-review","volume":"3","author":"Nimon","year":"2012","journal-title":"Front. Psychol."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0295","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/24\/1\/015104","article-title":"A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology","volume":"24","author":"Negi","year":"2013","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0300","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.colsurfb.2010.07.029","article-title":"Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC","volume":"81","author":"Gonzalez-Mira","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0305","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/10837450.2013.867445","article-title":"Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement","volume":"20","author":"Mandpe","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0310","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.canlet.2012.07.002","article-title":"Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer","volume":"334","author":"Yang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0315","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/20550324.2019.1710974","article-title":"Sonication amplitude and processing time influence the cellulose nanocrystals morphology and dispersion","volume":"6","author":"Jamileh","year":"2020","journal-title":"Nanocomposites"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0320","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.aca.2007.07.011","article-title":"Box-Behnken design\u202f: an alternative for the optimization of analytical methods","volume":"597","author":"Ferreira","year":"2007","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0325","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11356-011-0611-4","article-title":"Optimizing removal of ibuprofen from water by magnetic nanocomposite using Box-Behnken design","volume":"19","author":"Singh","year":"2012","journal-title":"Environ. Sci. Pollut. Res."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0330","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.reactfunctpolym.2016.01.011","article-title":"Mucoadhesion: a promising approach in drug delivery system","volume":"100","author":"Mansuri","year":"2016","journal-title":"React. Funct. Polym."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0335","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3390\/polym12081800","article-title":"Hyaluronic acid: the influence of molecular weight and degradable properties of biopolymer","volume":"12","author":"Snetkov","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.colsurfb.2005.08.005","article-title":"Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system","volume":"45","author":"Hu","year":"2005","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0345","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.xphs.2019.06.003","article-title":"Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies","volume":"108","author":"Singh","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0350","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpb.2007.01.015","article-title":"Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - development, physicochemical characterization and in vitro release studies","volume":"67","author":"Teeranachaideekul","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0355","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40005-017-0320-1","article-title":"Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles","volume":"47","author":"Son","year":"2017","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0360","doi-asserted-by":"crossref","first-page":"28955","DOI":"10.1039\/D3CP01855E","article-title":"Release of molecules from nanocarriers","volume":"25","author":"Zhdanov","year":"2023","journal-title":"PCCP"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0365","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40005-023-00630-1","article-title":"Amorphous nasal powder advanced performance: in vitro\/ex vivo studies and correlation with in vivo pharmacokinetics","volume":"53","author":"Henriques","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0370","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10717544.2014.885999","article-title":"Optimization of artemether-loaded NLC for intranasal delivery using central composite design","volume":"22","author":"Jain","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0375","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/733\/1\/012039","article-title":"A comparison of TEM and DLS methods to characterize size distribution of ceramic nanoparticles","volume":"733","author":"Souza","year":"2016","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0380","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.biopha.2017.12.103","article-title":"Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: in vitro and in vivo anesthesia evaluation","volume":"98","author":"Yue","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121939","article-title":"Hyaluronic acid coated teriflunomide (A771726) loaded lipid carriers for the oral management of rheumatoid arthritis","volume":"623","author":"Zewail","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0390","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2018.05.007","article-title":"Effect of formulation and process variables on lipid based sustained release tablets via continuous twin screw granulation: a comparative study","volume":"121","author":"Kallakunta","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0395","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.2147\/IJN.S104774","article-title":"Phytosome-hyaluronic acid systems for ocular delivery of L-carnosine","volume":"11","author":"Abdelkader","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0400","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s13346-023-01315-w","article-title":"Response surface optimization of a cardioprotective compound through pharmacosomal drug delivery system: in vivo bioavailability and cardioprotective activity potential","volume":"13","author":"Dawoud","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0405","doi-asserted-by":"crossref","first-page":"9462","DOI":"10.1039\/C9RA10867J","article-title":"Enhanced delivery of melatonin loaded nanostructured lipid carriers during: in vitro fertilization: NLC formulation, optimization and IVF efficacy","volume":"10","author":"Noori Siahdasht","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0410","article-title":"Nanostructured lipid carriers as a drug delivery system: a comprehensive review with therapeutic applications","author":"Mall","year":"2024","journal-title":"Intell Pharm"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0415","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1039\/C5RA19793G","article-title":"Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment","volume":"6","author":"Dadhania","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0420","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2478\/acph-2019-0024","article-title":"Metabolic stability and its role in the discovery of new chemical entities","volume":"69","author":"S\u0142oczy\u0144ska","year":"2019","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0425","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acsmedchemlett.8b00018","article-title":"Strategy for extending half-life in drug design and its significance","volume":"9","author":"Gunaydin","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0430","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1039\/D4PM00174E","article-title":"Pharmaceutics nose to brain targeting of the donepezil nanostructured lipid carrier in situ gel","author":"Sonawane","year":"2024","journal-title":"RSC Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0435","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejpb.2008.10.009","article-title":"Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue","volume":"72","author":"Horv\u00e1t","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0440","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00418-008-0410-2","article-title":"Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat","volume":"130","author":"Wolburg","year":"2008","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0445","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pharmaceutics16010066","article-title":"Nose-to-brain (N2B) delivery: an alternative route for the delivery of biologics in the management and treatment of central nervous system disorders","volume":"16","author":"Patharapankal","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0450","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0455","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0460","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0465","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0470","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1022592913323","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates","volume":"61","author":"Patel","year":"2003","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0475","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/17425247.2016.1092519","article-title":"Brain-blood ratio: implications in brain drug delivery","volume":"13","author":"Kulkarni","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0480","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3109\/10717544.2014.975382","article-title":"Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study","volume":"23","author":"Madane","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103371","article-title":"Intranasal delivery of biotechnology-based therapeutics","volume":"27","author":"Patel","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0490","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0495","article-title":"On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0500","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2013.04.084","article-title":"Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies","volume":"452","author":"Abdelbary","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0505","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/pharmaceutics14030572","article-title":"Pharmacokinetics and pharmacodynamics of intranasal solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain delivery","volume":"14","author":"Nguyen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0510","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0515","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2014.05.004","article-title":"Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug","volume":"470","author":"Alam","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0520","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","article-title":"Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies","volume":"29","author":"Elmowafy","year":"2021","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.ijbiomac.2025.143236_bb0525","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jddst.2019.02.017","article-title":"Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier","volume":"51","author":"Salvi","year":"2019","journal-title":"J Drug Deliv Sci Technol"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025037882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025037882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T06:57:45Z","timestamp":1762239465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025037882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":105,"alternative-id":["S0141813025037882"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143236","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyaluronate-incorporated edaravone nanostructured lipid carriers for nose-to-brain targeting- biphasic DoE optimization, pharmacokinetic, and brain distribution studies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"143236"}}